tegafur has been researched along with Disease Models, Animal in 25 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 7.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 5.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| " Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice." | 3.72 | Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. ( Fujioka, A; Fukushima, M; Kitazato, K; Nagayama, S; Nakagawa, F; Nukatsuka, M; Oshimo, H; Sugimoto, Y; Uchida, J, 2004) |
| "In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co." | 3.70 | Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ( Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K, 1999) |
| "Treatment of 'metastasis', in retrospect, usually involves minimal residual disease and therapy naïve tumors." | 2.44 | On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. ( Kerbel, RS; Man, S; Munoz, R, 2007) |
| " To expand the range of applications and investigate the clinical value of the combination strategy, the therapeutic benefit of metronomic S-1 dosing in combination with oxaliplatin (l-OHP)-containing PEG-coated liposomes was evaluated in a murine colon carcinoma-bearing mice model." | 1.36 | Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. ( Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Matsumoto, H; Okada, T, 2010) |
| "Human gastric cancer cells (MKN-45) were injected into the peritoneal cavity of nude mice." | 1.32 | Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil. ( Fujiwara, Y; Monden, M; Mori, T; Takiguchi, S; Tamura, S; Yano, M; Yasuda, T, 2003) |
| " Since clinical studies have demonstrated that bisphosphonates (BPs), specific inhibitors of osteoclastic bone resorption, are beneficial for breast cancer patients with bone metastases, we next examined the effects of UFT combined with the BP zoledronic acid (ZOL) on established bone metastases." | 1.32 | Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. ( Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T, 2003) |
| " These findings demonstrate that administration of S-1 to patients with impaired renal function may need individualized dosing and pharmacokinetic monitoring." | 1.31 | Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. ( Furukawa, H; Ikeda, M; Imamura, H; Ishida, H; Kawasaki, T; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M, 2002) |
| "To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice." | 1.31 | [Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 17 (68.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ide, H | 1 |
| Kikuchi, E | 1 |
| Hasegawa, M | 1 |
| Hattori, S | 1 |
| Yasumizu, Y | 1 |
| Miyajima, A | 1 |
| Oya, M | 1 |
| Kajiwara, T | 1 |
| Miura, K | 1 |
| Ohnuma, S | 1 |
| Shimada, M | 1 |
| Komura, T | 1 |
| Toshima, M | 1 |
| Kohyama, A | 1 |
| Kudoh, K | 1 |
| Haneda, S | 1 |
| Musha, H | 1 |
| Naitoh, T | 1 |
| Shirasaka, T | 2 |
| Unno, M | 1 |
| Yanagihara, K | 1 |
| Tsumuraya, M | 1 |
| Takigahira, M | 1 |
| Mihara, K | 1 |
| Kubo, T | 1 |
| Ohuchi, K | 1 |
| Seyama, T | 1 |
| Doi, Y | 1 |
| Okada, T | 1 |
| Matsumoto, H | 1 |
| Ichihara, M | 1 |
| Ishida, T | 1 |
| Kiwada, H | 1 |
| Sadahiro, S | 2 |
| Suzuki, T | 2 |
| Maeda, Y | 1 |
| Tanaka, A | 1 |
| Okada, K | 1 |
| Kanoda, H | 1 |
| Kamijo, A | 1 |
| Ikeda, M | 1 |
| Furukawa, H | 1 |
| Imamura, H | 1 |
| Shimizu, J | 1 |
| Ishida, H | 1 |
| Masutani, S | 1 |
| Tatsuta, M | 1 |
| Kawasaki, T | 1 |
| Satomi, T | 1 |
| Mori, T | 3 |
| Fujiwara, Y | 3 |
| Yano, M | 3 |
| Tamura, S | 3 |
| Yasuda, T | 3 |
| Takiguchi, S | 3 |
| Monden, M | 3 |
| Hiraga, T | 1 |
| Ueda, A | 1 |
| Tamura, D | 1 |
| Hata, K | 1 |
| Ikeda, F | 1 |
| Williams, PJ | 1 |
| Yoneda, T | 1 |
| Takahashi, Y | 1 |
| Yamashita, K | 1 |
| Endo, Y | 1 |
| Sasaki, T | 1 |
| Mai, M | 1 |
| Matsumoto, S | 1 |
| Igishi, T | 1 |
| Hashimoto, K | 1 |
| Kodani, M | 1 |
| Shigeoka, Y | 1 |
| Nakanishi, H | 1 |
| Touge, H | 1 |
| Kurai, J | 1 |
| Makino, H | 1 |
| Takeda, K | 1 |
| Yasuda, K | 1 |
| Hitsuda, Y | 1 |
| Shimizu, E | 1 |
| Nukatsuka, M | 2 |
| Fujioka, A | 2 |
| Nakagawa, F | 3 |
| Oshimo, H | 1 |
| Kitazato, K | 1 |
| Uchida, J | 2 |
| Sugimoto, Y | 2 |
| Nagayama, S | 1 |
| Fukushima, M | 3 |
| Tsujimoto, H | 1 |
| Tsukioka, S | 1 |
| Koizumi, K | 1 |
| Oka, T | 1 |
| Watanabe, T | 1 |
| Katoh, R | 1 |
| Ooshiro, M | 1 |
| Man, S | 1 |
| Munoz, R | 1 |
| Kerbel, RS | 1 |
| Miyauchi, S | 1 |
| Imaoka, T | 1 |
| Utsunomiya, T | 1 |
| Hayashi, K | 1 |
| Kubo, M | 1 |
| Kawaguchi, T | 1 |
| Matsui, Y | 1 |
| Cao, S | 1 |
| Lu, K | 1 |
| Tóth, K | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Nishimura, G | 1 |
| Yanoma, S | 1 |
| Satake, K | 1 |
| Ikeda, Y | 1 |
| Taguchi, T | 1 |
| Nakamura, Y | 1 |
| Hirose, F | 1 |
| Tsukuda, M | 1 |
| Basaki, Y | 1 |
| Aoyagi, K | 1 |
| Chikahisa, L | 1 |
| Miyadera, K | 1 |
| Hashimoto, A | 1 |
| Yonekura, K | 1 |
| Okabe, S | 1 |
| Shibata, J | 1 |
| Wierzba, K | 1 |
| Yamada, Y | 1 |
| Makuuchi, H | 1 |
| Tokunaga, N | 1 |
| Ishizu, K | 1 |
| Tajima, T | 1 |
| Tsutsumi, S | 1 |
| Kuwano, H | 1 |
| Morinaga, N | 1 |
| Shimura, T | 1 |
| Asao, T | 1 |
| Iino, Y | 1 |
| Ohshimo, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for tegafur and Disease Models, Animal
| Article | Year |
|---|---|
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclophosphamide; Disease Models, Animal; Drug Com | 2007 |
24 other studies available for tegafur and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2013 |
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combinations; Fluorouracil; G | 2015 |
An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Transformed; Cell Prolife | 2010 |
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2010 |
[Pharmacokinetic study of S-1 for the treatment of peritoneal metastasis from colon cancer--using a mouse peritoneal metastasis model].
Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Drug Com | 2010 |
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cisplatin; Disease Models, Animal; Drug Combinations | 2002 |
Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2003 |
Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Disease Models, Animal; Drug Combinations; Ea | 2003 |
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bo | 2003 |
Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2004 |
Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cel | 2004 |
Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disea | 2004 |
[Benefits of TS-1 plus leucovorin combination therapy for colorectal cancer: evaluation of therapeutic effect of TS-1 and leucovorin combination therapy using rodent model fed a low folate diet].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Models, | 2007 |
Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Colonic Neoplasms; Disease Models, Animal; Dr | 2007 |
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Dru | 1994 |
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combin | 1999 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
Topics: Air Sacs; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Carcinoma, Rena | 2000 |
A novel weekday-on/weekend-off UFT schedule.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Animal model of para-aortic lymph node metastasis.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Squamous | 2001 |
Treatment of tamoxifen-refractory breast cancer--approach by animal models.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; | 2001 |
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Topics: Aminoacridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
[Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Drug Combina | 2002 |